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ARTICLE
Urological cancer patients receiving treatment during COVID-
19: a single-centre perspective
Sophie Therese Williams1, Salma El Badri2 and Syed Anwer Hussain 1
BACKGROUND: Active cancer, immunosuppressive treatments and immunotherapies have been reported to increase cancer
patients’ risk of developing severe COVID-19 infection. For patients and clinicians, treatment risk must be weighed against disease
progression.
METHODS: This retrospective case series surveys urological cancer patients who made informed decisions to continue anticancer
treatment (ACT) at one centre from March to June 2020.
RESULTS: Sixty-one patients (44 bladder, 10 prostate, 7 upper urinary tract cancers) received 195 cycles of ACT (99 chemotherapy,
59 immunotherapy, 37 as part of ongoing clinical trials), with a range of indications: 43 palliative, 10 neoadjuvant, 8 adjuvant. One
patient tested positive for COVID-19 but experienced only mild symptoms. Fourteen patients interrupted treatment outside of their
schedule, seven of these due to potential COVID-19 associated risk. ACT supportive steroids were not associated with higher rates
of COVID-19.
CONCLUSIONS: This single-centre series reports that ACT administration did not result in an apparent excess in symptomatic
COVID-19 infections.
British Journal of Cancer https://doi.org/10.1038/s41416-021-01263-7
BACKGROUND
The evolving COVID-19 pandemic, caused by Severe Acute
Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), is a huge
concern for oncologists and cancer patients. Early reports
suggested active cancer, immunosuppressive treatments and
immunotherapy (IO) increased patients’ risk of developing severe
COVID-19 infection.1,2 Early discussions of risk also focused on
potential side effects of IO, requiring immunosuppressive
agents such as steroids. Concern was raised regarding service
provision, hospital attendance and infection exposure during
treatment.3 NICE published guidance on how best to prioritise
treatments, in the event that treatments needed to be rationa-
lised, based on likelihood of cure, or extending life beyond
12 months.4
In urothelial cancers, there is an established evidence base for
both palliative chemotherapy and immunotherapy,5,6 and
advanced disease can progress quickly without palliative che-
motherapy.7 For patients and clinicians, the risks from COVID-19
infection have to be weighed against the personalised risks of
disease progression without treatment.
METHODS
Retrospective data were collected for all patients who attended
for ACT for urological cancer between 1 March 2020 and 30 June
2020, under the care of one consultant at one centre (adjoined to
infectious diseases, ICU and critical care services). Data were
collected by review of electronic chemotherapy prescriptions,
written and electronic clinical notes in the second week of July.
Data included: demographic, diagnosis, ACT regimen, including
presence or absence of supportive steroid, any reason for ACT
interruption, emergency admissions. Biochemical results, oxygen
requirement, NEWS-2 score on admission and COVID status were
recorded if admitted to our centre or regional hospitals within
South Yorkshire. All patients were screened for COVID-19
symptoms and contacts on entry to the hospital and on arrival
at the chemotherapy day case unit. All patients receiving ACT
were advised to follow the government’s advice on shielding. The
potential risks of COVID-19 were discussed with all patients,
including the potential implications should they require
hospitalisation.
RESULTS
Sixty-one patients (44 bladder, 10 prostate and 7 upper urinary
tract primary cancers) received a total of 195 cycles of anticancer
therapy: 99 cycles of chemotherapy, 59 immunotherapy and a
further 37 cycles of treatment as part of ongoing clinical trials (see
Table 1). Median age was 71 (47–87) and included 41 men (67%).
All patients had an ECOG performance status of 0 (41, 67%) or 1
(20, 33%) at clinical review. Metastatic disease was present in 45
patients (74%): 36 had visceral metastases and 9 had lymph-node
only metastatic disease. There was a range of indications for
treatment: 43 palliative, 10 neoadjuvant and 8 adjuvant. Across all
patients, 48 had at least one comorbidity (79%), with hypertension
being the most prevalent (21, 34%), followed by hearing
impairment (9, 15%) and raised cholesterol (8, 13%). With regards
to concomitant use of steroids, 10 patients received a 3-day
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course of dexamethasone with 21 days of prednisolone (as per
standard Docetaxel chemotherapy regimen), while 29 patients
received a short course (3 days) of dexamethasone as an
antiemetic with a number of chemotherapy regimens (see Table 1).
Two patients received an extended course of high dose
prednisolone (>21 days) for immunotherapy-associated hepatitis
(Grade 2 and Grade 3), neither of whom contracted COVID-19. The
patient with Grade 3 hepatotoxicity was rechallenged with
Atezolizumab in May 2020 without any adverse event.
One patient tested COVID-19 positive while admitted for
treatment-associated complications: they experienced mild
COVID-19 symptoms that were managed on a ward and did not
require oxygen therapy. Ten other patients required emergency
admission to hospital, not related to COVID-19. Three patients had
elective admissions: two had radical cystectomy following
neoadjuvant chemotherapy and one had a nephrostomy insertion.
All patients admitted, except two, were tested for COVID-19 with
only one positive result as described above. Only symptomatic
patients were tested for COVID-19 at the start of the pandemic,
but the hospital policy changed in April 2020 to testing all
admissions.
Fourteen patients interrupted treatment outside of their
planned schedule. Seven were due to individual risk and COVID-
19 (including the COVID-19 positive patient reported above),
while the additional seven were due to non-COVID causes
including: disease progression,3 immunotherapy-associated hepa-
titis,2 neutropenic sepsis1 and ischaemic stroke.1 This patient, with
T2 N0 M0 bladder cancer, developed an ischaemic stroke after
three cycles of neoadjuvant chemotherapy and was referred for
radical, surgical treatment omitting the final cycle of
chemotherapy.
DISCUSSION
This retrospective case series reports on the outcomes of patients
who received systemic ACT during the peak of the first wave of
COVID-19 infections in the UK. The demographics of these
patients reflect a typical urological cancer cohort fit for systemic
treatment: median age of 71, predominantly male with a
performance status of 0 or 1 and relatively few comorbidities. In
a 3-month comparable pre-COVID period, Sept 1 to Dec 31, 2019,
59 patients received 166 cycles of ACT, showing that clinical
practice during our observation period was not dramatically
reduced.
Only one patient tested positive for COVID-19 on admission to
hospital for other reasons. This in part reflects the dedication of
patients to following social distancing and shielding advice, but
needs to be considered alongside the regional infection rate (R0),
which in Sheffield has been reported as 0.983, the third highest
local authority infection rate in the country as of the last week of
June.8 It also demonstrates that of the 195 cycles given, and
necessary treatment-associated visits, social distancing and
screening questions were effective in preventing COVID-19
transmission. No patients required ICU level support or had died
due to COVID-19 as of July 15, 2020, but it is important to note
that ICU and critical care services were stretched throughout our
study period. Our results are in keeping with the findings of Lee
et al., who, after adjusting for age, sex and comorbidities, found no
significant association between chemotherapy or immunotherapy
in the past 4 weeks and mortality from COVID-19.9
Guidelines have advised avoiding the use of IO during COVID-
19 because of the proposed risk of severe disease in immuno-
suppression resulting from IO-associated toxicity treatment with
steroids.4,10 However, local and national observational studies
have now refuted this mechanism.9,11 In fact, dexamethasone is
now evidenced for treatment of COVID-19 infected patients
requiring supplemental oxygen and or ventilation.12 For patients
treated at our centre, IO treatment and IO toxicity treated with
steroids did not result in COVID-19 infection.
It should be emphasised that this is retrospective data from a
single institution, by a single consultant and only details the
results for a narrow spectrum of cancers. We only captured
patients who received treatment, not all patients who may have
been considered for systemic treatment, including patients who
decided to proceed with radical surgical treatment without
neoadjuvant chemotherapy, or patients who declined adjuvant
chemotherapy after surgery. We also may not have captured
patients who have been COVID-19 positive in the community, but
who did not seek medical attention or report symptoms at clinic
or chemo-suite attendance.
Table 1. Patient anticancer therapy (ACT) regimens March 1 to June 30, 2020.
Type Treatment Steroid Standard duration (days) Cycles Patients
IO Atezoliazumab — — 51 12
IO Pembrolizumab — — 8 2
CHEMO Carbo/Etoposide DEX 3 7 2
CHEMO Cis1/Gem1+ 8 DEX 3 17 6
CHEMO Cis1+ 8/Gem1+ 8 DEX 3 33 15a
CHEMO Docetaxel DEX/PRED 3/21 28 10
CHEMO Gemc/Carbo DEX 3 7 3
CHEMO Paclitaxel DEX 3 7 2a
TRIAL POTOMAC (Durvalumab) — — 18 4
TRIAL JAVELIN (Avelumab) — — 4 1
TRIAL NIAGARA (Cis/Gem) — — 5 2
TRIAL STRONG (Durvalumab) — — 4 1
TRIAL ASTELLAS (Enfortumab) — — 4 1
TRIAL ASTELLAS (Paclitaxel) DEX 3 2 1
Total — — — 195 61a
Duration of steroid in days. Patients receiving treatment on the ASTELLAS trial are presented by treatment type.
DEX dexamethasone, PRED prednisolone, IO immunotherapy, CHEMO chemotherapy, TRIAL patients receiving treatment on treatment on existing clinical trials.
aOne patient received two treatments (Paclitaxel followed by Cis1+ 8/Gem1+ 8), making a total of 61 patients.
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This single-centre, retrospective case series shows that patients were
keen to continue treatment where possible, that ACT could be
administered in a safe environment that did not result in an
apparent excess in symptomatic COVID-19 infections. The admin-
istration of supportive steroids did not result in higher rates of
infection, or severe disease, and that rates of chemotherapy and
immunotherapy-associated complications were no higher than in
pre-COVID-19 times. Our data demonstrates that treatment with
systemic chemotherapy, immune checkpoint inhibitors and the use
of steroids for toxicity management may be possible during the
current COVID-19 pandemic, as now supported by Lee et al. and the
RECOVERY trials.9,12 As the NHS begins routine clinical work again,
patients need to make informed decisions after careful discussion
with their oncologists about their treatments, and require careful
review of risks from ACT, COVID-19 and disease progression.
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